Novartis Neupogen Biosimilar: On Sale Now

Sep 03, 2015

Novartis' Zarxio -- the first U.S. biosimilar drug -- is on sale for 15% less than the original drug, Amgen's blockbuster, Neupogen.

The U.S.-based biotech Amgen was fighting to stop the sale of Zarxio by Novartis's Sandoz unit, but a Washington-based appeals court rejected its attempt to block the launch.

Neupogen boosts white blood cell counts to fight infections in cancer patients. According to the WSJ, the U.S. market accounted for more than 70% of Amgen’s $1.16 billion in sales of Neupogen last year.

Read the Sandoz press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments